注射胶原酶与有限的筋膜切除术治疗杜普伊特伦挛缩症。

IF 96.2 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL
New England Journal of Medicine Pub Date : 2024-10-24 Epub Date: 2024-10-09 DOI:10.1056/NEJMoa2312631
Joseph Dias, Puvanendran Tharmanathan, Catherine Arundel, Charlie Welch, Qi Wu, Paul Leighton, Maria Armaou, Nick Johnson, Sophie James, John Cooke, Lionel Bainbridge, Michael Craigen, David Warwick, Samantha Brady, Lydia G Flett, Judy Jones, Catherine N Knowlson, Michelle Watson, Ada Keding, Catherine E Hewitt, David Torgerson
{"title":"注射胶原酶与有限的筋膜切除术治疗杜普伊特伦挛缩症。","authors":"Joseph Dias, Puvanendran Tharmanathan, Catherine Arundel, Charlie Welch, Qi Wu, Paul Leighton, Maria Armaou, Nick Johnson, Sophie James, John Cooke, Lionel Bainbridge, Michael Craigen, David Warwick, Samantha Brady, Lydia G Flett, Judy Jones, Catherine N Knowlson, Michelle Watson, Ada Keding, Catherine E Hewitt, David Torgerson","doi":"10.1056/NEJMoa2312631","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Treatments for Dupuytren's contracture include limited fasciectomy and collagenase injection. Comparisons of the effectiveness of these treatments have been limited.</p><p><strong>Methods: </strong>We performed an unblinded, multicenter, pragmatic, two-group, randomized, controlled noninferiority trial comparing collagenase injection with limited fasciectomy in persons with moderate Dupuytren's contracture. The primary outcome was the score on the Patient Evaluation Measure-Hand Health Profile (PEM), a questionnaire for assessing hand health as reported by the patient, at 1 year after treatment. Scores on the PEM range from 0 to 100, with higher scores indicating worse outcomes. The prespecified noninferiority margin was 6 points.</p><p><strong>Results: </strong>A total of 672 persons (336 per group) were assigned to receive collagenase injection or to undergo limited fasciectomy. The primary analysis included 599 persons: 314 in the collagenase group and 285 in the limited-fasciectomy group. The mean score on the PEM at 1 year was 17.8 among the 284 patients with available data in the collagenase group and 11.9 among the 250 patients with available data in the limited-fasciectomy group (estimated difference, 5.9 points; 95% confidence interval [CI], 3.1 to 8.8; one-sided P = 0.49 for noninferiority). Among the patients with available data (229 patients in the collagenase group and 197 patients in the limited-fasciectomy group), the estimated difference in the mean score on the PEM at 2 years was 7.2 points (95% CI, 4.2 to 10.9). Moderate or severe complications of treatment occurred in 1.8% of the patients in the collagenase group and in 5.1% of those in the limited-fasciectomy group; recurrent contracture resulted in reintervention in 14.6% and 3.4%, respectively.</p><p><strong>Conclusions: </strong>Collagenase injection was not noninferior to limited fasciectomy with respect to the score on the PEM at 1 year after treatment. (Funded by the National Institute for Health and Care Research Health Technology Assessment Programme; DISC ISRCTN Registry number ISRCTN18254597.).</p>","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":96.2000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7616701/pdf/","citationCount":"0","resultStr":"{\"title\":\"Collagenase Injection versus Limited Fasciectomy for Dupuytren's Contracture.\",\"authors\":\"Joseph Dias, Puvanendran Tharmanathan, Catherine Arundel, Charlie Welch, Qi Wu, Paul Leighton, Maria Armaou, Nick Johnson, Sophie James, John Cooke, Lionel Bainbridge, Michael Craigen, David Warwick, Samantha Brady, Lydia G Flett, Judy Jones, Catherine N Knowlson, Michelle Watson, Ada Keding, Catherine E Hewitt, David Torgerson\",\"doi\":\"10.1056/NEJMoa2312631\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Treatments for Dupuytren's contracture include limited fasciectomy and collagenase injection. Comparisons of the effectiveness of these treatments have been limited.</p><p><strong>Methods: </strong>We performed an unblinded, multicenter, pragmatic, two-group, randomized, controlled noninferiority trial comparing collagenase injection with limited fasciectomy in persons with moderate Dupuytren's contracture. The primary outcome was the score on the Patient Evaluation Measure-Hand Health Profile (PEM), a questionnaire for assessing hand health as reported by the patient, at 1 year after treatment. Scores on the PEM range from 0 to 100, with higher scores indicating worse outcomes. The prespecified noninferiority margin was 6 points.</p><p><strong>Results: </strong>A total of 672 persons (336 per group) were assigned to receive collagenase injection or to undergo limited fasciectomy. The primary analysis included 599 persons: 314 in the collagenase group and 285 in the limited-fasciectomy group. The mean score on the PEM at 1 year was 17.8 among the 284 patients with available data in the collagenase group and 11.9 among the 250 patients with available data in the limited-fasciectomy group (estimated difference, 5.9 points; 95% confidence interval [CI], 3.1 to 8.8; one-sided P = 0.49 for noninferiority). Among the patients with available data (229 patients in the collagenase group and 197 patients in the limited-fasciectomy group), the estimated difference in the mean score on the PEM at 2 years was 7.2 points (95% CI, 4.2 to 10.9). Moderate or severe complications of treatment occurred in 1.8% of the patients in the collagenase group and in 5.1% of those in the limited-fasciectomy group; recurrent contracture resulted in reintervention in 14.6% and 3.4%, respectively.</p><p><strong>Conclusions: </strong>Collagenase injection was not noninferior to limited fasciectomy with respect to the score on the PEM at 1 year after treatment. (Funded by the National Institute for Health and Care Research Health Technology Assessment Programme; DISC ISRCTN Registry number ISRCTN18254597.).</p>\",\"PeriodicalId\":54725,\"journal\":{\"name\":\"New England Journal of Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":96.2000,\"publicationDate\":\"2024-10-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7616701/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"New England Journal of Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1056/NEJMoa2312631\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"New England Journal of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1056/NEJMoa2312631","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/9 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:杜普伊特伦挛缩症的治疗方法包括有限筋膜切除术和胶原酶注射。这些治疗方法的有效性比较一直很有限:我们对中度杜普伊特伦挛缩症患者进行了一项非盲法、多中心、务实、两组随机对照非劣效性试验,比较胶原酶注射与有限筋膜切除术。试验的主要结果是治疗 1 年后患者在 "患者评估量表-手部健康档案"(PEM)上的得分,这是一份由患者报告的手部健康评估问卷。PEM 分数范围为 0 到 100 分,分数越高,疗效越差。预设的非劣效差为 6 分:共有 672 人(每组 336 人)被分配接受胶原酶注射或有限筋膜切除术。主要分析包括 599 人:胶原酶注射组 314 人,有限筋膜切除术组 285 人。在胶原酶注射组中,284 名有数据可查的患者 1 年后的 PEM 平均得分为 17.8 分,而在有限筋膜切除术组中,250 名有数据可查的患者 1 年后的 PEM 平均得分为 11.9 分(估计差异为 5.9 分;95% 置信区间 [CI],3.1 至 8.8;单侧 P = 0.49 表示非劣效)。在有可用数据的患者中(胶原酶组 229 例,有限筋膜切除术组 197 例),2 年后 PEM 平均得分的估计差异为 7.2 分(95% 置信区间 [CI],4.2 至 10.9)。胶原酶注射组有1.8%的患者出现了中度或严重的治疗并发症,局限性筋膜切除术组有5.1%的患者出现了中度或严重的并发症;分别有14.6%和3.4%的患者因复发性挛缩而再次接受治疗:结论:就治疗后 1 年的 PEM 评分而言,胶原酶注射并不优于有限筋膜切除术。(由美国国家健康与护理研究所健康技术评估计划资助;DISC ISRCTN 注册号为 ISRCTN18254597)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Collagenase Injection versus Limited Fasciectomy for Dupuytren's Contracture.

Background: Treatments for Dupuytren's contracture include limited fasciectomy and collagenase injection. Comparisons of the effectiveness of these treatments have been limited.

Methods: We performed an unblinded, multicenter, pragmatic, two-group, randomized, controlled noninferiority trial comparing collagenase injection with limited fasciectomy in persons with moderate Dupuytren's contracture. The primary outcome was the score on the Patient Evaluation Measure-Hand Health Profile (PEM), a questionnaire for assessing hand health as reported by the patient, at 1 year after treatment. Scores on the PEM range from 0 to 100, with higher scores indicating worse outcomes. The prespecified noninferiority margin was 6 points.

Results: A total of 672 persons (336 per group) were assigned to receive collagenase injection or to undergo limited fasciectomy. The primary analysis included 599 persons: 314 in the collagenase group and 285 in the limited-fasciectomy group. The mean score on the PEM at 1 year was 17.8 among the 284 patients with available data in the collagenase group and 11.9 among the 250 patients with available data in the limited-fasciectomy group (estimated difference, 5.9 points; 95% confidence interval [CI], 3.1 to 8.8; one-sided P = 0.49 for noninferiority). Among the patients with available data (229 patients in the collagenase group and 197 patients in the limited-fasciectomy group), the estimated difference in the mean score on the PEM at 2 years was 7.2 points (95% CI, 4.2 to 10.9). Moderate or severe complications of treatment occurred in 1.8% of the patients in the collagenase group and in 5.1% of those in the limited-fasciectomy group; recurrent contracture resulted in reintervention in 14.6% and 3.4%, respectively.

Conclusions: Collagenase injection was not noninferior to limited fasciectomy with respect to the score on the PEM at 1 year after treatment. (Funded by the National Institute for Health and Care Research Health Technology Assessment Programme; DISC ISRCTN Registry number ISRCTN18254597.).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
New England Journal of Medicine
New England Journal of Medicine 医学-医学:内科
CiteScore
145.40
自引率
0.60%
发文量
1839
审稿时长
1 months
期刊介绍: The New England Journal of Medicine (NEJM) stands as the foremost medical journal and website worldwide. With an impressive history spanning over two centuries, NEJM boasts a consistent publication of superb, peer-reviewed research and engaging clinical content. Our primary objective revolves around delivering high-caliber information and findings at the juncture of biomedical science and clinical practice. We strive to present this knowledge in formats that are not only comprehensible but also hold practical value, effectively influencing healthcare practices and ultimately enhancing patient outcomes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信